AstraZeneca says Wainua failure won’t alter M&A plans, stays on track for $80B 2030 goal

AstraZeneca said during its Q2 earnings presentation that the late‑stage failure of the antisense therapy Wainua in ATTR‑cardiomyopathy does not derail its goal of reaching $80 billion in revenue by 2030.

Chief financial officer Aradhana Sarin told reporters the setback has no impact on the company’s M&A strategy, and CEO Pascal Soriot added that failures are expected and the firm does not need acquisitions to deliver growth, citing a broad pipeline of candidates.

The company also disclosed several other clinical disappointments, mainly in its cancer portfolio, but framed them as part of a larger set of positive study outcomes and said they will not change its overall business‑development approach.